Acute Myeloid Leukemia, Cancer, Malignant Disease, Myelodysplastic Syndromes, Relapsed Hematologic Malignancy, Solid Tumor
Conditions
Keywords
atorvastatin, p53, tumor resection
Brief summary
This is a window-of-opportunity trial to determine if atorvastatin given for 1 to 4 weeks at a dose of 80 milligrams per day (mg/day) is sufficient to decrease the level of conformational mutant tumor protein 53 (p53) in malignant diseases (solid tumor and relapsed Acute Myeloid Leukemia (AML)).
Interventions
DRUGAtorvastatin
Atorvastatin tablet, 80mg
Sponsors
Joaquina Baranda
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Ability of participant to understand this study, and participant to sign a written informed consent. Legally authorized representative is not allowed to sign consent for participant. * Participants with tumor protein 53 (TP53) immunohistochemistry (IHC)-positive tumors * Participants whose screening IHC shows TP53-IHC-negative including wild type (WT) and null. * Participants with histologic or cytologic confirmation of any malignant disease who are planning and eligible to undergo surgical resection. For participants with Solid Tumors Only * Participants with previously treated acute myeloid leukemia (AML) are eligible if they relapse and are in between two treatment regimens * No concurrent or recent (within 30 days) use of systemic therapy including chemotherapy, immunotherapy, hormonal therapy, cancer vaccine, or local therapy for the cancer. * Formalin-fixed paraffin-embedded (FFPE) tumor tissue deemed adequate for IHC analysis and next generation sequencing (NGS) are required. Bone marrow aspirate tissue samples from participants with AML are required. * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Adequate organ and marrow function * A negative urine or serum pregnancy test within 7 days before Day 1 dose of study medication, if female participant is of childbearing potential. * Women of child-bearing potential and men with partners of child-bearing potential must agree to practice sexual abstinence, or to use two forms of adequate contraception (hormonal AND barrier method of birth control) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. If a woman becomes pregnant or suspects she is pregnant while participating in this study, she should inform her treating physician immediately.
Exclusion criteria
* Current or anticipated use of other investigational agents while participating in this study. * Pregnant or breast feeding. * Diagnosis of squamous cell cancer of the oropharynx * Previous malignancies (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, endometrial, cervical/dysplasia, melanoma, or breast), unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required during the study period * Prior use of statins in the past 30 days. * History of rhabdomyolysis * Active liver disease * Participants who currently consume substantial quantities of alcohol (Male, more than 4 drinks a day, Female, more than 2 drinks a day) * Concurrent use of drugs associated with myopathy * Hypersensitivity to atorvastatin or any component of the formulation * Untreated hypothyroidism * Inability to comply with study and follow-up procedures as judged by the Investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in conformational mutant tumor protein 53 (p53) | baseline and up to 4 weeks | Measured by immunohistochemistry (IHC) staining. Reported as overall percent difference in the level of conformation mutant p53. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Ki-67 (protein) | baseline and up to 4 weeks | Measured by immunohistochemistry (IHC) staining. Reported as overall percent difference in the level of Ki-67 (also known as MKI67) in the conformation mutant p53 samples. |
| Change in caspase-3 | baseline and up to 4 weeks | Measured by immunohistochemistry (IHC) staining. Reported as overall percent difference in the level of caspase-3 in the conformation mutant p53 samples. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORJoaquina Baranda, MD
The University of Kansas Cancer Center
Outcome results
None listed